Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome

The Eisenmenger syndrome corresponds to the most advanced form of pulmonary arterial hypertension associated with congenital heart disease. The syndrome causes chronic hypoxemia, with an increase in erythrocyte mass, which predisposes to thrombotic complications. Pentoxifylline is a xanthine derivative and it is considered as a hemorrheological agent with described effects of reduction in erythrocyte and platelet aggregation, adhesion and activation of leukocytes, and endothelial damage. The main objective of this study is to verify if the chronic oral administration of pentoxifylline to Eisenmenger patients induces an increase in the circulating levels of thrombomodulin, a naturally occurring proteoglycan with anticoagulant, anti thrombotic and anti-inflammatory properties.

NCT Number	NCT05611268
Lead Sponsor	University of Sao Paulo General Hospital Collaborators: InCor Heart Institute
Conditions	Eisenmenger Syndrome
Enrollment	48 participants
Start Date	2022-06-03
Primary Completion	2024-09-30 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2023-12-15